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medical intervention is not wishful thinking, it is proven. It
is clear, for instance, that the effectiveness and imple-
mentation of arterial disease medical intervention has
steadily improved over the last 20e30 years such that
carotid surgery (or stenting) can no longer be considered
routine for asymptomatic, moderate or severe carotid
stenosis.1 In fact, the potential role of relatively high-risk
and expensive procedures, like carotid surgery for stroke
prevention, needs to be redefined and will relate to
a much smaller proportion of patients than previously
assumed.
Among patients with moderateesevere asymptomatic
carotid stenosis, we are now seeing average annual ipsi-
lateral stroke rates of around 0.5% with current medical
intervention alone, rates about 5 times lower than non-
operated patients in the Asymptomatic Carotid Athero-
sclerosis Study2 (the only randomised trial showing an
overall surgical benefit with respect to ipsilateral stroke)
and about 3 times lower than operated patients from the
same trial. Medical intervention is an evolving, powerful,
multidisciplinary combination of interventions to avoid or
minimise the impact of atherosclerotic disease, including
ongoing diagnosis of arterial disease risk factors, education,
support of healthy life style practices and appropriate drug
usage.1 Current evidence indicates that it alone is now best
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efficacy, it is at least 4e8 times cheaper in preventing
stroke than surgery as employed in the randomised trials, it
protects against other complications of arterial disease and
because high-risk patients who benefit from additional
surgery or stenting cannot be identified.1,3
With current medical intervention alone, compared to
randomized trial patients, fewer patients with carotid
stenosis will become symptomatic. Those who become
symptomatic will probably have a better prognosis with
respect to recurrent stroke symptoms, whether or not they
undergo carotid endarterectomy. Therefore, the 6% 30-day
perioperative stroke/death rate4 used currently as the
benchmark for an overall surgical stroke prevention benefit
for symptomatic stenosis is undoubtedly too high in the
context of current medical intervention and needs re-
measurement.5
Previously it was not known what specifically reduces
risk of stroke caused by carotid atherosclerosis. Patients
were largely treated by referring clinicians according to
other recognized arterial risk factors (like hypertension and
non-ipsilateral carotid symptoms of arterial disease). Like
today, medical intervention was hampered by many issues,
including an incomplete understanding of its effectiveness,
incomplete definition, incomplete monitoring of its utili-
zation and limited compliance. However, it must be
understood that despite these problems, it is now clear
that medical intervention has improved sufficiently to over-
turn previous expectations regarding the role of procedures
like surgery in stroke prevention, expectations based on
results of two or three trials in which patients were rand-
omised long ago (1983e2003).2,6e8 What more could bed by Elsevier Ltd. All rights reserved.
510 A. Abbottachieved if we upgraded efforts to minimise barriers to
utilizing current, optimal medical intervention?
We need to make sure clinicians, patients, health-
service funders and the general public understand the
superior efficacy and cost-effectiveness of current arterial
disease medical intervention. For many reasons our socie-
ties should not continue to recommend unnecessary, rela-
tively high-risk and expensive procedures for stroke
prevention. Nor should we accept a general culture of
neglecting the power we each have to reduce our own risk
and maintain healthy arteries with simple, non-invasive and
relatively cheap measures.
To ensure the great effectiveness of current medical
intervention is delivered to our communities, routine clin-
ical practice needs to become organized. First, we need to
state what we accept as current, best evidence-based
recommendations about how to best prevent complications
of atherosclerosis, including prevention of stroke (and
other complications) associated with both asymptomatic
and symptomatic carotid atherosclerosis, whether or not
patients are undergoing procedures like carotid or cardiac
surgery. Second, we need to incorporate basic, accurate
self-auditing such that each practice has objective
measures of patient risk factor load, interventions given
and fundamental outcomes achieved. Only then we will
have current, locally relevant information to allow us to
judge whether or not patients are being managed optimally
and address reasons for underutilization, like inadequate
clinician, patient or community awareness, drug side-
effects and cost management issues. These efforts to
organize routine practice must be ongoing to accommodate
evolving medical intervention and allow development of
large, meaningful data sets. Such efforts will be far more
powerful than an ongoing reliance on relatively few and
infrequent studies of relatively few patients from relatively
remote locations.
In addition, we need to continue efforts to identify
new risk factors, and combination of risk factors,9 which
better stratify risk despite current optimal medical
intervention. We need to continue efforts to make
medical intervention increasingly effective and cost-
effective. I applaud the authors of the article ‘Best
Medical Therapy or Wishful Thinking in Carotid Disease’,10
for taking steps to address some of these issues and
encouraging others to follow!Conflict of interest/Funding
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